Citations

Clear

30 citation(s) found for "Saw, J J".

Standardized endpoint definitions for trials of transcatheter left atrial appendage closure: a consensus from the Left Atrial Appendage Academic Research Consortium
Garot, Philippe , Mehran, Roxana , Backer, Ole De , Freeman, James V. , Wunderlich, Nina, Hibbert, Benjamin , Tzikas, Apostolos , Nair, Devi, Berti, Sergio, Saw, Jacqueline , Freixa, Xavier, Doshi, Shephal K. , Cruz-Gonzalez, I, Coylewright, Megan, Aminian, Adel, Sanchis, L, Ruff, Christian T, Landmesser, Ulf, Lakkireddy, Dhanunjaya , Alasnag, Mirvat, Yamamoto, Masanori , Iwamoto, Shin, Shiba, Takeshi , Jin, Y Z, Jagadeesan, Vikrant, Krucoff, Mitchell W., Nielsen-Kudsk, Jens Erik, Gibson, C Michael, Gurol, Edip Mahmut, Cutlip, Don E, Leon, Martin B, Holmes, David R. , Morice, M C, Alkhouli, Mohamad, De Backer, Ole , Räber, Lorenz , Lakkireddy, Dhanunjaya , Ellis, Christopher , Yamamoto, Masanori , Schmidt, Boris , Hildick-Smith, David , Oliva, Angelo , Spitzer, Ernest , Holmes, David R , Mehran, Roxana , Hibbert, Benjamin , Freeman, James V , Tzikas, Apostolos , Freixa, Xavier , Cruz‐González, Ignacio , Coylewright, Megan , Aminian, Adel , Price, Matthew J. , Räber, Lorenz , Yao, Xiaoxi , Sanchís, Laura , Ruff, Christian Thomas , Landmesser, Ulf , Ellis, Christopher R. , Alasnag, Mirvat , Ferro, Enrico Giuseppe , Shiba, Takeshi, Jin, Yu, Reddy, Vivek Y. , Spitzer, Ernest , Nielsen‐Kudsk, Jens Erik , Gibson, C. Michael , Gurol, M. Edip , Cutlip, Donald E. , Leon, Martin B. , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag482 | PMID 42425446 Get It

Abstract Since its introduction in 2002, left atrial appendage closure (LAAC) has rapidly expanded as an alternative to anticoagulation in patients with atrial fibrillation at high risk of stroke. Harmonized processes for data collection, analysis, and reporting in LAAC trials are essential to enhance research quality and improve clinical practice. The Left Atrial Appendage Academic Research Consortium (LAARC) initiative is an independent collaboration of academic research organizations, cardiology and neurology experts, clinical trialists, and regulatory authorities from the USA, Europe, and Asia. The consortium engaged clinical experts, regulators—including the US Food and Drug Administration (FDA), European Notified Bodies, and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)—and industry leaders to define standardized study elements and endpoints for LAAC trials. Key considerations included alignment with prior Academic Research Consortium initiatives, procedural and mechanistic insights, and clinical relevance. Consensus definitions were proposed for mortality, stroke, bleeding, and device performance, along with composite endpoints for safety and effectiveness. The proposed LAARC consensus definitions aim to standardize endpoint reporting, improve comparability across studies, and support regulatory and clinical trial applications for this evolving therapy through broad dissemination in the peer-reviewed literature.
A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
Balsay-Patel, Caitlyn , Dugan, Michelle, Naqvi, Syeda Mahrukh Hussnain , Ollila, D. W., Houdt, Winan J. van, Asher, Nethanel, Snow, Hayden, Farma, Jeffrey M., Vetto, John T. , Saw, Robyn P.M., LO, S, Long, Georgina V., Ny, Lars, Akkooi, Alexander Christopher Jonathan Van, Bagge, Roger Olofsson, Zager, Jonathan S., Long, Georgina V. , Akkooi, Alexander C. J. van , Saw, Robyn P.M. , Lo, Serigne , Long, Georgina V , Lo, Serigne N , Dugan, Michelle M. , Hieken, Tina J. , Houdt, Winan J. van , Asher, Nethanel , Broman, Kristy K. , Farma, Jeffrey M. , Hui, Jane Yuet Ching , Ny, Lars , Kim, Youngchul , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9524-9524

10.1200/jco.2026.44.16_suppl.9524 Get It

9524 Background: Unresectable melanoma in-transit metastases (ITM) can pose a significant clinical challenge. Our recently published data comparing first-line treatments for ITM, isolated limb infusion or perfusion (ILI/ILP), immune checkpoint inhibitors (ICI) and intralesional talimogene laherparepvec (TVEC), found superior outcomes with TVEC. However, TVEC was used more often in patients with lower disease burden and earlier stage (IIIB vs. IIIC/D). Therefore, we sought to better investigate these differences with a propensity score-matched (PSM) analysis. Methods: A multi-institutional, international IRB- approved retrospective analysis was conducted for unresectable melanoma ITM from 2016-2022. PSM analysis comparing first-line ILI/ILP, ICI, and TVEC for was performed. Patients were matched for stage, number of ITM, anatomical site, CLND status, gender and age. Kaplan-Meier curves (OS, PFS, DMFS) and Cumulative incidence function (MSS) were used to visualize time-to-event outcomes in the PSM cohort, though both methods do not account for the matched structure. Results: 274 patients were identified, 120 female/154 male; 96 treated with ILI/ILP, 111 with ICI, and 67 with TVEC. Median follow-up was 40 months (range, 1-80). PSM was performed and identified 36 TVEC–ICI pairs and 27 TVEC–ILI pairs. These were combined resulting in a final cohort of 108 observations (45 TVEC, 36 ICI and 27 ILI). The groups were well balanced. No statistical difference was found for metastasis-free survival (DMFS), progression-free survival (PFS), melanoma-specific survival (MSS), and overall survival (OS) between treatment modalities. TVEC was associated with significant improvement in local PFS (median was 2.2 years (y) for ILI/ILP, 1.5y for ICI and not reached for TVEC, p=0.048). While not statistically significant, a clinical benefit was seen in PFS being longer for TVEC (2.1y for TVEC vs. 1.2y for ILI/ILP and 1.1y for ICI; p=0.2) and OS (not reached vs 2.9y for ILI/ILP and 5.2y for ICI; p=0.2). On mixed effect Cox regression proportional hazard model using the matched data set, there were no significant differences in any of the survival and recurrence outcomes. Conclusions: When patients are propensity-matched, there were no significant differences in first-line treatment modalities for unresectable melanoma ITM. Treatment with TVEC did result in clinically meaningful improved overall and local PFS and OS. This supports that selection of ITM therapy should incorporate an individualized approach, incorporating disease distribution, stage, burden, treatment side effects and patient priorities.
Recurrent Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Left Atrial Appendage Occlusion
Ramadan, Adham, Doma, Mohamed , Félix, Iuri Ferreira , Ahmed, Mahmoud Samy, Mahmoud, Ahmed K., Ismayl, Mahmoud, Karara, Yehia , Villablanca, Pedro A., Saw, J, DeSimone, Christopher V., Doma, Mohamed , Ferreira Felix, Iuri , Mahmoud, Ahmed K , DeSimone, Christopher V , Ramadan, Adham, Kamel, Ibrahim, Ismayl, Mahmoud , Villablanca, Pedro, Saw, Jacqueline , DeSimone, Christopher V. , Goldsweig, Andrew M.

Mayo Clinic

Pacing and Clinical Electrophysiology | February 21, 2026 | Volume: 49 | Issue: 7 | Pages: 898-910

10.1111/pace.70177 | PMID 41721735 Get It

ABSTRACT Background Concomitant atrial fibrillation (AF) and gastrointestinal (GI) bleeding present a clinical challenge due to recurrent bleeding risk associated with anticoagulation for AF‐associated stroke prevention. Left atrial appendage occlusion (LAAO) offers an alternative stroke prevention strategy, but its impact on recurrent GI bleeding remains unknown. Methods This retrospective, multicenter cohort study used the TriNetX database to identify adults with AF on oral anticoagulation and a history of GI bleeding. Patients were stratified by treatment with or without LAAO. 1:1 propensity score matching (PSM) was employed. The primary outcome was recurrent GI bleeding. Cox regression analysis was used to generate hazard ratios (HRs) with 95% confidence intervals (CIs). Odds ratios (ORs) were used to evaluate effect sizes between groups. Kaplan–Meier curves were used for time‐to‐event analyses. Results After PSM, 9259 patients were compared in each group. Odds of recurrent GI bleeding were consistently lower in patients undergoing LAAO than without LAAO across all follow‐up intervals: at 3 months (OR 0.84; 95% CI 0.78–0.91), 6 months, 1 year, 3 years, and 5 years (OR 0.87; 95% CI 0.82–0.92). Kaplan–Meier analysis demonstrated significantly lower risk of recurrent GI bleeding with LAAO (HR 0.80; 95% CI 0.76–0.84; p < 0.01). Conclusion In patients with AF and prior GI bleeding, LAAO was associated with a significantly lower risk of recurrent GI bleeding at short‐term and long‐term time intervals.
Sex Differences in Psychological Distress of Patients With Spontaneous Coronary Artery Dissection (SCAD): The MINDSET Study
Maukel, Lisa‐Marie , Coutinho, Thais D. , Mulvagh, Sharon L. , Madan, Mina , Pacheco, Christine , Bouchard, Karen , So, Derek , Saw, Jacqueline, Reed, Jennifer , Liu, Shuangbo , Sun, Louise Y. , Robert, Helen Mary, Lappa, N., Tulloch, Heather E., Bouchard, Karen , Reed, Jennifer L. , So, Derek Y , Saw, Jacqueline , E Tulloch, Heather , Liu, Shuangbo , Saw, Jacqueline , Paquin, Amélie , Robert, Helen, Tulloch, Heather

Mayo Clinic

Circulation: Population Health and Outcomes | January 13, 2026 | Volume: 19 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.125.012626 | PMID 41697327 Get It

BACKGROUND: Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndrome, predominantly affecting women. Psychological distress is common pre- and post-SCAD, yet sex-specific patterns remain understudied. This cross-sectional study aimed to examine sex differences in the psychological distress of patients with SCAD. METHODS: Adult patients diagnosed with SCAD within the past 3 years, confirmed by coronary angiography, were recruited from 6 Canadian hospitals between April 2022 and January 2025. Participants completed questionnaires assessing sociodemographics and validated measures of psychological distress: Patient Health Questionnaire-9 for depression, Generalized Anxiety Disorder-7 for generalized anxiety, Cardiac Anxiety Questionnaire for cardiac-related anxiety, and PTSD Checklist-5 for posttraumatic stress symptoms. Sex differences were analyzed using t tests for continuous variables and χ 2 tests for categorical variables. Multivariable linear regression models assessed the association between sex and psychological distress, adjusting for age, pre-SCAD mental health diagnosis, and employment status. RESULTS: Among 326 patients (92.9% women; mean age=53.3±11.1 years), women reported higher rates of preexisting mental health conditions (29.2% versus 8.7%; P =0.035). Post-SCAD women reported higher mean scores than men on the Patient-Health-Questionnaire-9, Cardiac-Anxiety-Questionnaire, and PTSD Checklist-5 (all P <0.05). Female sex was associated with greater depressive (B=2.94; P =0.010), cardiac anxiety (B=7.09; P =0.008), and posttraumatic stress symptoms (B=5.94; P =0.048) after adjustment. Clinically significant symptoms were more common in women versus men: 25.1% versus 0% (depression), 21.5% versus 4.4% (anxiety), 54.8% versus 26.1% (cardiac anxiety), and 15.5% versus 0% (posttraumatic stress). CONCLUSIONS: Both women and men experience clinically significant cardiac anxiety following SCAD, but women report a greater psychological burden, including more preexisting mental health conditions and twice the distress after SCAD. These results underscore the importance of routine psychological screening and timely intervention to support mental health and recovery outcomes, particularly among women.
Abstract 4341827: Double Trouble — Exploring Mental Health Issues in Patients with Spontaneous Coronary Artery Dissection (SCAD) and Fibromuscular Dysplasia (FMD)
Coutinho, Thais , Madan, Mina , So, Derek , Saw, Jacqueline , Wells, George A. , Sun, Louise Y. , Robert, Helen Mary, Lappa, N., Tulloch, Heather , Maukel, Lisa‐Marie , Mulvagh, Sharon L. , Pacheco, Christine , Bouchard, Karen , Reed, Jennifer L. , Liu, Shuangbo , Robert, Helen

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4341827 Get It

Background: Spontaneous Coronary Artery Dissection (SCAD) is a cause of acute coronary syndrome, particularly among women, and is associated with psychological distress, including depression, anxiety, and post-traumatic stress (PTSD) symptoms. Fibromuscular dysplasia (FMD), a vascular condition that alters the arteries, is often found in patients with SCAD, adding complexity and uncertainty with a second serious diagnosis. This study examined the differences in mental health symptoms between SCAD survivors with and without FMD to better understand their unique psychosocial needs and inform interventions to enhance patient outcomes. Methods: Patients diagnosed with SCAD within the past 3 years were recruited from 6 Canadian cardiac hospitals. Participants completed questionnaires assessing socio-demographics, comorbidities, and validated psychological measures, including Patient Health Questionnaire-9 (PHQ-9) for depression, Generalized Anxiety Disorder-7 (GAD-7) for generalized anxiety, Cardiac Anxiety Questionnaire (CAQ) for cardiac-related anxiety, and PTSD Checklist (PCL-5) for PTSD symptoms. Differences in mental health outcomes between SCAD survivors with and without FMD were analyzed using t-tests for continuous variables and chi-square tests for categorical variables. Results: The study included 326 participants (92.9% female; mean age 53.3 years), with 67 participants (20.6%) having a confirmed diagnosis of FMD at the time of questionnaire completion (39.3% FMD at study completion). Post-SCAD, patients with FMD reported significantly higher scores than patients without FMD on the GAD-7 (6.4±5.9 vs. 4.7±4.9, p = .028), CAQ (29.9±13.1 vs. 26.0±12.3, p = .023), and PCL-5 (17.2±15.4 vs. 13.3± 14.0, p = .048). The proportion of SCAD survivors with FMD scoring in the clinically diagnostic range was significantly higher than those in patients without FMD: 32.8% vs. 20.8% for depression, 31.3% vs. 17.4% for anxiety, 64.2% vs. 49.2% for cardiac anxiety, and 25.4% vs. 11.6% for PTSD (all p < .05). Conclusions: Our findings suggest that SCAD survivors with comorbid FMD experience significantly higher distress —depression, generalized anxiety, cardiac-related anxiety, and PTSD symptoms—compared to those without FMD. Longitudinal research is needed to explore the role of these mental health concerns in long-term mental health and cardiac outcomes. Enhanced psychological interventions for those with FMD may be required.
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Borgeaud, Maxime , Olivier, Timothée , Bar, Jair , Saw, Stephanie P.L. , Parikh, Kaushal , Banna, Giuseppe Luigi , Vito, Claudio De , Feldman, Jill , Le, Xiuning , Addeo, Alfredo , Saw, Stephanie Pei Li , De Vito, Claudio , Addeo, Alfredo , Olivier, Timothée , Feldman, Jill

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 17, 2025 | Volume: 75 | Issue: 5 | Pages: 387-409

10.3322/caac.70024 | PMID 40673977 Get It

AbstractThe discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR‐mutant non‐small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression‐free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co‐mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR‐mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
DePalo, Danielle K. , Dugan, Michelle M. , Naqvi, Syeda Mahrukh Hussnain , Ollila, David W. , Hieken, Tina J. , Block, Matthew S. , Houdt, Winan J. van , Reijers, Sophie J. M. , Asher, Nethanel , Duncan, Zoey , Anderson, Matilda, Snow, Hayden , Held, Jenny M., Farma, Jeffrey M. , Vetto, John T. , Hui, Jane Yuet Ching , Kolbow, Madison , Saw, Robyn P.M. , Lo, Serigne , Long, Georgina V. , Karapetyan, Lilit , Akkooi, Alexander C. J. van , van Houdt, Winan J , Asher, Nethanel , Hui, Jane Yuet Ching , Kolbow, Madison , Lo, Serigne N , Thompson, John F , Zager, Jonathan S , Hieken, Tina J , Long, Georgina V , Wouters, Michel W.J.M. , Broman, Kristy K. , Gyorki, David E. , Held, Jenny, Thompson, John F. , Kim, Youngchul , Ny, Lars , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Cancer | November 10, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35636 | PMID 39522025 Get It

AbstractBackgroundIsolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in‐transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene laherparepvec [TVEC]) introduced several different management options. This study compares first‐line ILI/ILP, ICI, and TVEC.MethodsRetrospective review from 12 international institutions included patients treated from 1990 to 2022 with first‐line ILI/ILP, ICI, or TVEC for unresectable melanoma ITM.ResultsA total of 551 patients were treated, with ILI/ILP (n = 356), ICI (n = 125), and TVEC (n = 70) with median follow‐up of 5.5 years. Tumor burden was highest with ILI/ILP and lowest with TVEC (p = .002). Breslow thickness was lowest with TVEC (p = .007). TVEC was mostly used in stage IIIB disease versus IIIC for ILI/ILP and ICI (p = .01). Using ICI as the reference category, TVEC had the highest odds of a complete response (CR) (odds ratio, 1.96; p = .029) and a longer local progression‐free survival (PFS) (hazard ratio [HR], 0.40; p = .003). ILI/ILP had shorter local PFS (HR, 1.72; p = .012), PFS (HR, 1.79; p < .001), distant metastasis‐free survival (DMFS) (HR, 1.75; p = .014), overall survival (HR, 1.82; p = .009), and melanoma‐specific survival (HR, 2.29; p = .004). Stage IIIB disease had longer DMFS (HR, 0.24; p < .001) compared to IIIC/D.ConclusionsTVEC as first‐line therapy for unresectable melanoma ITM was associated with superior CR rates and local PFS. Notably, TVEC was used in patients with a lower Breslow thickness, disease stage, and tumor burden. Therefore, when compared to ILI/ILP and ICI, TVEC should be considered as first‐line therapy for unresectable stage IIIB melanoma ITM with minimal tumor burden and lower Breslow thickness.
Bacterial and Fungal Communities Entombed Within Calcium Oxalate, Struvite, and Brushite Human Kidney Stones
Lange, Dirk , Dong, Yiran, Merkel, Annette, Krambeck, Amy E. , Rivera, Marcelino , Large, Tim , Weber, Joseph R. , Fouke, Bruce W. , Wilson, Elena M., Saw, Jessica J. , Sivaguru, Mayandi , Sanford, Robert A. , Fields, Christopher J. , Cregger, Melissa A. , Bruce, William J. , Lieske, John C. , Chia, Nicholas , Romero, Michael F.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 682-682

10.1681/asn.20203110s1682b Get It

Neuromuscular Complications of Graft Versus Host Disease (S42.008)
Saw, Jacqui‐Lyn , Sidiqi, M Hasib , Alkhateeb, Hassan B. , Naddaf, Elie

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s42.008 Get It

Thermoregulatory Sweat Testing in Sensory Neuronopathies (P3.6-052)
Saw, Jacqui‐Lyn , Windebank, Anthony J. , Berini, Sarah E.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p3.6-052 Get It